ValuEngine cut shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) from a sell rating to a strong sell rating in a research report sent to investors on Thursday.

A number of other analysts have also weighed in on the company. Canaccord Genuity set a $7.00 target price on Aptose Biosciences and gave the company a buy rating in a research note on Wednesday, November 15th. Zacks Investment Research cut Aptose Biosciences from a buy rating to a sell rating in a report on Friday, December 15th. Finally, HC Wainwright set a $4.00 price target on Aptose Biosciences and gave the company a buy rating in a report on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Aptose Biosciences has an average rating of Hold and a consensus target price of $5.00.

Shares of Aptose Biosciences (NASDAQ:APTO) opened at $2.80 on Thursday. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $3.90.

A hedge fund recently raised its stake in Aptose Biosciences stock. Acadian Asset Management LLC boosted its position in Aptose Biosciences Inc (NASDAQ:APTO) (TSE:APS) by 316.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 44,421 shares of the biotechnology company’s stock after acquiring an additional 33,766 shares during the period. Acadian Asset Management LLC owned 0.17% of Aptose Biosciences worth $100,000 at the end of the most recent quarter. 1.07% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with's FREE daily email newsletter.